From: Antibiotic resistance as a global threat: Evidence from China, Kuwait and the United States
From Tables 1,2,3,8 and 9; Unit: % | |||||
---|---|---|---|---|---|
Bacterium(a) | Antibiotic(s) | Pair | China | U.S. | Kuwait |
SAU | Methicillin | A | 37 | 38 | 9 |
SPN | Erythromycin | B | 73 | 19 | 23 |
Cefotaxime | C | 0 | 16 | 4 | |
Enterococcus spp | Vancomycin | D | 4 | 10 | 0 |
ECO | Ceftazidime | E | 9 | 1* | 5 |
Cefotaxime | F | 18 | 1* | 1 | |
Ceftriaxone | G | 21 | 1* | 1 | |
Ciprofloxacin/Ofloxacin | H | 56 | 3 | 26 | |
PAE | Ceftazidime | I | 17 | 9 | 27 |
Ciprofloxacin/Ofloxacin | J | 27 | 28 | 31 | |
KPN | Ceftazidime | K | 9 | 4* | 14 |
Cefotaxime | L | 17 | 4* | 13 | |
Ceftriaxone | M | 20 | 4* | 13 | |
Ciprofloxacin | N | 18 | 12**[27] | 18 | |
Salmonella spp | Amoxicillin-clavulanate | O | 10 | 4 | 7 |
Ceftriaxone | P | 5 | 1 | 0 | |
Ciprofloxacin | Q | 0 | 0.4 | 10 | |
TMP/SMX*** | R | 0 | 3 | 0 | |
Gentamicin | S | 10 | 2 | 0 | |
Shigella spp | Amoxicillin-clavulanate | T | 35 | 2 | 20 |
Ceftriaxone | U | 6 | 0 | 0 | |
Ciprofloxacin | V | 6 | 0 | 0 | |
TMP/SMX | W | 0 | 53 | 0 | |
Gentamicin | X | 18 | 0.2 | 0 | |
Average | 17 | 7 | 9 |